Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Trends in High-grade Cervical Lesions and Cervical Cancer Screening in Five States, 2008-2015.

Gargano JW, Park IU, Griffin MR, Niccolai LM, Powell M, Bennett NM, Johnson Jones ML, Whitney E, Pemmaraju M, Brackney M, Abdullah N, Scahill M, Dahl RM, Cleveland AA, Unger ER, Markowitz LE; HPV-IMPACT Working Group.

Clin Infect Dis. 2018 Aug 23. doi: 10.1093/cid/ciy707. [Epub ahead of print]

PMID:
30137283
2.

Prevalence of Vaccine Type Infections in Vaccinated and Non-Vaccinated Young Women: HPV-IMPACT, a Self-Sampling Study.

Jeannot E, Viviano M, de Pree C, Amadane M, Kabengele E, Vassilakos P, Petignat P.

Int J Environ Res Public Health. 2018 Jul 9;15(7). pii: E1447. doi: 10.3390/ijerph15071447.

3.

Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008-2012.

Hariri S, Markowitz LE, Bennett NM, Niccolai LM, Schafer S, Bloch K, Park IU, Scahill MW, Julian P, Abdullah N, Levine D, Whitney E, Unger ER, Steinau M, Bauer HM, Meek J, Hadler J, Sosa L, Powell SE, Johnson ML; Hpv-Impact Working Group.

Emerg Infect Dis. 2015 Sep;21(9):1557-61. doi: 10.3201/eid2109.141841.

4.

Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States.

Hariri S, Johnson ML, Bennett NM, Bauer HM, Park IU, Schafer S, Niccolai LM, Unger ER, Markowitz LE; HPV-IMPACT Working Group.

Cancer. 2015 Aug 15;121(16):2775-81. doi: 10.1002/cncr.29266. Epub 2015 Jun 22.

5.

Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012.

Hariri S, Bennett NM, Niccolai LM, Schafer S, Park IU, Bloch KC, Unger ER, Whitney E, Julian P, Scahill MW, Abdullah N, Levine D, Johnson ML, Steinau M, Markowitz LE; HPV-IMPACT Working Group.

Vaccine. 2015 Mar 24;33(13):1608-13. doi: 10.1016/j.vaccine.2015.01.084. Epub 2015 Feb 11.

PMID:
25681664
6.

HPV type attribution in high-grade cervical lesions: assessing the potential benefits of vaccines in a population-based evaluation in the United States.

Hariri S, Unger ER, Schafer S, Niccolai LM, Park IU, Bloch KC, Bennett NM, Steinau M, Johnson ML, Markowitz LE; HPV-IMPACT Working Group.

Cancer Epidemiol Biomarkers Prev. 2015 Feb;24(2):393-9. doi: 10.1158/1055-9965.EPI-14-0649. Epub 2014 Nov 21.

7.

Sources of information for assessing human papillomavirus vaccination history among young women.

Niccolai LM, McBride V, Julian PR; Connecticut HPV-IMPACT Working Group.

Vaccine. 2014 May 23;32(25):2945-7. doi: 10.1016/j.vaccine.2014.03.059. Epub 2014 Apr 5.

PMID:
24713369
8.

Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions.

Powell SE, Hariri S, Steinau M, Bauer HM, Bennett NM, Bloch KC, Niccolai LM, Schafer S, Unger ER, Markowitz LE.

Vaccine. 2012 Dec 17;31(1):109-13. doi: 10.1016/j.vaccine.2012.10.092. Epub 2012 Nov 6.

PMID:
23137842
9.

Human papillomavirus genotypes in high-grade cervical lesions in the United States.

Hariri S, Unger ER, Powell SE, Bauer HM, Bennett NM, Bloch KC, Niccolai LM, Schafer S, Steinau M, Markowitz LE; HPV-IMPACT Working Group.

J Infect Dis. 2012 Dec 15;206(12):1878-86. doi: 10.1093/infdis/jis627. Epub 2012 Oct 8.

PMID:
23045628
10.

The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions.

Hariri S, Unger ER, Powell SE, Bauer HM, Bennett NM, Bloch KC, Niccolai LM, Schafer S, Markowitz LE; HPV-IMPACT Working Group.

Cancer Causes Control. 2012 Feb;23(2):281-8. doi: 10.1007/s10552-011-9877-6. Epub 2011 Nov 23.

PMID:
22108842

Supplemental Content

Loading ...
Support Center